Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 6, Pages 553-559
Publisher
Informa UK Limited
Online
2018-06-02
DOI
10.1080/13543784.2018.1484107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
- (2017) Howard I. Scher et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2017) Nicolas Mottet et al. EUROPEAN UROLOGY
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
- (2016) Athanasios Dellis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel and next-generation androgen receptor–directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
- (2016) Richard M. Bambury et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
- (2015) DJ Crona et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Observational studies and the natural history of screen-detected prostate cancer
- (2015) Peter C. Albertsen CURRENT OPINION IN UROLOGY
- Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
- (2015) Theodoros Karantanos et al. EUROPEAN UROLOGY
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment
- (2015) Michael S. Cookson et al. JOURNAL OF UROLOGY
- Androgen receptor aberrations in the era of abiraterone and enzalutamide
- (2015) Florian Jentzmik et al. WORLD JOURNAL OF UROLOGY
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
- (2013) Paul J Toren et al. ASIAN JOURNAL OF ANDROLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started